A review of soft-tissue sarcomas: translation of biological advances into treatment measures

@inproceedings{Hoang2018ARO,
  title={A review of soft-tissue sarcomas: translation of biological advances into treatment measures},
  author={Ngoc Thi Hong Hoang and Luis A. Manzanero Acevedo and Michael J Mann and Bhairavi Tolani},
  booktitle={Cancer management and research},
  year={2018}
}
Soft-tissue sarcomas are rare malignant tumors arising from connective tissues and have an overall incidence of about five per 100,000 per year. While this diverse family of malignancies comprises over 100 histological subtypes and many molecular aberrations are prevalent within specific sarcomas, very few are therapeutically targeted. Instead of utilizing molecular signatures, first-line sarcoma treatment options are still limited to traditional surgery and chemotherapy, and many of the latter… CONTINUE READING
8
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 210 REFERENCES

Phase II trial of ribociclib and everolimus in advanced dedifferentiated liposarcoma (DDL) and leiomyosarcoma (LMS). Available from: https://clinicaltrials.gov/ct2/show/ NCT03114527

Fox Chase Cancer Center
  • NLM identifier: NCT03114527. Accessed March
  • 2018
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2012
VIEW 14 EXCERPTS
HIGHLY INFLUENTIAL

Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma

MD Anderson Cancer Center
  • Available from: https://clinicaltrials.gov/ct2/show/NCT03307616. NLM identifier: NCT03307616. Accessed March
  • 2018
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

EWS/FLI is a Master Regulator of Metabolic Reprogramming in Ewing Sarcoma.

  • Molecular cancer research : MCR
  • 2017
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2016
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL

Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma

  • Molecular therapy : the journal of the American Society of Gene Therapy
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Recurrent PTPRB and PLCG1 mutations in angiosarcoma

  • Nature Genetics
  • 2014
VIEW 7 EXCERPTS
HIGHLY INFLUENTIAL